FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Medexus Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Medexus Pharmaceuticals Inc. (MEDXF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMEDXF
MEDXF
Medexus Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MEDXF
Home🔹Stocks🔹Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

MEDXF•OTC

Medexus Pharmaceuticals Inc.

MEDXF•OTC
Market cap
$68.15M
Sentiment

Your view on MEDXF

Mkt Cap
$68.15M
Sentiment
Your view
MEDXF
Medexus Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MEDXF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Medexus Pharmaceuticals Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kenneth d'Entremont
Headquarters
35 Nixon Road, Bolton, ON, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kenneth d'Entremont
Headquarters
35 Nixon Road, Bolton, ON, CA
Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News